CRBP241220C75000
- 0.45
- 0.000.00%
Corbus Pharmaceuticals Newsroom
Corbus Pharmaceuticals to Present at the 7th Annual Evercore HealthCONx Conference
Corbus Pharmaceuticals to Present at the Jefferies London Healthcare Conference
We're Not Very Worried About Corbus Pharmaceuticals Holdings' (NASDAQ:CRBP) Cash Burn Rate
RBC Capital Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Cuts Target Price to $65
Corbus Pharmaceuticals (CRBP) Receives a Buy From RBC Capital
Oppenheimer Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Maintains Target Price $60
Corbus Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
H.C. Wainwright Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Cuts Target Price to $75
Express News | Corbus Pharmaceuticals Holdings Inc : RBC Cuts Target Price to $65 From $82
Corbus Pharmaceuticals Reports Q3 2024 Financial Results
Corbus Pharmaceuticals Had $159.4M in Cash, Cash Equivalents and Investments on Hand as of Sept 30 >CRBP
Express News | Corbus Pharmaceuticals Reports 3Rd Quarter 2024 Financial Results and Provides a Corporate Update
Express News | Corbus Pharmaceuticals Q3 Operating Expenses USD 15.505 Million
Corbus Pharmaceuticals 3Q Loss/Shr $1.15 >CRBP
H.C. Wainwright Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Maintains Target Price $80
Corbus Pharmaceuticals' CRB-913: A Promising and Safer Alternative in Obesity Treatment With a Buy Rating
Corbus Pharmaceuticals Presents New CRB-913 Pre-Clinical Data At Obesity Week 2024
Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference
Oppenheimer Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Cuts Target Price to $60
Mizuho Securities Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating